An Alzheimer’s drug, NeuroEPO (brand name NeuralCIM), is currently in the final stages of clinical trials in Cuba. Cuba is collaborating with Canadian scientists at the University of Saskatchewan to run a confirmatory clinical trial on the drug. In Cuban trials, NeuroEPO has shown promising results in patients with early-stage Alzheimer’s. The trial was conducted at the Center of Molecular Immunology (Centro de Inmunología Molecular or CIM), a cancer research center in Havana.
